Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SLC27A1 | Q6PCB7 | 3/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13438882 | 0.94 | MAPT (0.46) | MAPTALDH1A1HTTLMNAL3MBTL1 | |
| SCHEMBL1645949 | 0.88 | MAPT (0.49) | MAPTALDH1A1HTTLMNAL3MBTL1 | |
| SCHEMBL13438987 | 0.84 | HTT (0.41) | MAPTALDH1A1HTTLMNAL3MBTL1 | |
| SCHEMBL13438885 | 0.83 | MAPT (0.46) | MAPTALDH1A1HTTLMNAL3MBTL1 | |
| SCHEMBL1645660 | 0.83 | ALDH1A1 (0.48) | MAPTALDH1A1HTTLMNAL3MBTL1 | |
| SCHEMBL13438880 | 0.82 | ALDH1A1 (0.51) | MAPTALDH1A1HTTLMNAL3MBTL1 | |
| SCHEMBL1644702 | 0.78 | MAPT (0.52) | MAPTALDH1A1HTTLMNAL3MBTL1 | |
| SCHEMBL1646239 | 0.76 | ALDH1A1 (0.53) | MAPTALDH1A1HTTLMNAL3MBTL1 | |
| SCHEMBL13438883 | 0.76 | HTR1A (0.51) | MAPTALDH1A1HTTLMNAL3MBTL1 | |
| SCHEMBL13462594 | 0.75 | SMN1; SMN2 (0.48) | MAPTALDH1A1HTTLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD. | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | NAT1, AGXT, CYP1A2 | MAPT 2950/4885ALDH1A1 318/4885HTT 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.